Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.

Cancer letters - 1 Mar 2024

Steiner Sabrina, Pliego-Mendieta Alicia, Haberecker Martina, Hussung Saskia, Kollár Anna, Fritsch Ralph, Arnold Fabian, Lenggenhager Daniela, Planas-Paz Lara, Pauli Chantal

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to late detection and limited treatment options. Some PDAC patients harbor alterations that qualify for targeted treatment strategies but develop acquired resistance, leading to treatment failure. We here report the ex vivo modeling of acquired drug resistance by creating a PDAC patient-derived tumor organoid (PDTO) model harboring a rare BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Organoids

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38246222
DOI: 10.1016/j.canlet.2024.216650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.PMID 38246222Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy.Semantic proximity Read ↗

Molecular Profiling and High-Content Drug Screening of Metastatic Colorectal Cancer Organoids Reveal Evolutionary Mechanisms of Pan-KRAS Inhibitor ResistanceSemantic proximity Read ↗

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Semantic proximity Read ↗

Patient-derived xenografts and organoids model therapy response in prostate cancerSemantic proximity Read ↗

Patient-derived urachal cancer organoids for personalized drug screeningSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.Semantic proximity Read ↗

Patient-derived xenografts and organoids model therapy response in prostate cancer.Semantic proximity Read ↗

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.